Daiwa Securities Group Inc. Reduces Stock Holdings in argenx SE (NASDAQ:ARGX)

Daiwa Securities Group Inc. lessened its position in argenx SE (NASDAQ:ARGX) by 5.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 845 shares of the company’s stock after selling 52 shares during the quarter. Daiwa Securities Group Inc.’s holdings in argenx were worth $363,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its position in shares of argenx by 23.1% during the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after buying an additional 37 shares during the last quarter. Wahed Invest LLC grew its position in argenx by 9.6% during the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after buying an additional 40 shares during the period. GAMMA Investing LLC increased its holdings in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in argenx by 3.1% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after purchasing an additional 43 shares during the period. Finally, Toronto Dominion Bank lifted its position in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after buying an additional 43 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft raised argenx from a “hold” rating to a “buy” rating in a research note on Thursday, July 25th. Truist Financial increased their target price on shares of argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Wells Fargo & Company boosted their price target on shares of argenx from $543.00 to $547.00 and gave the stock an “overweight” rating in a research note on Friday, July 26th. Bank of America reiterated a “buy” rating and issued a $607.00 price objective (up previously from $535.00) on shares of argenx in a research note on Monday, June 24th. Finally, Guggenheim lifted their price objective on shares of argenx from $545.00 to $585.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus target price of $547.74.

argenx Trading Down 0.0 %

NASDAQ ARGX opened at $537.94 on Tuesday. argenx SE has a 1 year low of $327.73 and a 1 year high of $554.74. The firm’s fifty day moving average price is $505.20 and its two-hundred day moving average price is $428.02. The firm has a market capitalization of $32.17 billion, a P/E ratio of -95.04 and a beta of 0.62.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same quarter last year, the business posted ($1.69) EPS. On average, research analysts anticipate that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.